摘要
血管新生是肿瘤发生发展中一个重要的病理特征,抗血管新生已经成为肿瘤治疗研究的一大热点.目前抗血管新生的策略主要是应用血管新生刺激因子拮抗剂或血管新生抑制因子,以抑制肿瘤异常增加的血管新生.相比于血管新生刺激因子拮抗剂,内源性血管新生抑制因子展现出更好的治疗前景,但是其分子机制还有待进一步阐明.内源性血管新生抑制因子包括两类,一类是前体蛋白的水解片段,如人纤溶酶原K5(plasminogen kringle 5,K5)、血管抑素(angiostatin/kringle 1~4)、内皮抑素(endostatin)等;另一类是细胞分泌性的蛋白质,如色素上皮衍生因子(pigment epithelium-derived factor,PEDF)、激肽释放酶结合蛋白(kallikrein-binding protein,KBP)、抗凝血酶(antithrombin)等.本文主要以本课题组研究的PEDF,KBP和K5为例,分别介绍其生物学功能、抗肿瘤血管新生机制及应用前景等方面的研究进展,希望这些研究能够为未来肿瘤抗血管新生治疗提供借鉴.
Angiogenesis is one of the most important pathological characteristics in the development of tumor growth. Hence, antiangiogenesisis a hot topic in the field of cancer research. The current strategy for antiangiogenesis therapy of tumors is restoration of theangiogenic balance via either blockage of proangiogenic factors or application of angiogenic inhibitors. Endogenous angiogenicinhibitors show more promising prospects compared with proangiogenic factor antagonists. However, the underlying mechanisms ofangiogenic inhibitors remain to be thoroughly elucidated. There are two types of endogenous angiogenic inhibitors. The first arehydrolyzed fragments of precursor proteins, such as plasminogen kringle 5 (K5), angiostatin/kringle 1–4, and endostatin, and theother are secreted proteins, such as pigment epithelium-derived factor (PEDF), kallikrein-binding protein (KBP/kallistatin), andantithrombin. Here we summarized research progress on the biological functions underlying mechanisms of tumor angiogenesis andapplication prospects of K5, PEDF, and KBP, so as to provide insights into the antiangiogenic therapies of tumor in the future.
作者
杨霞
杨中汉
周倜
齐炜炜
高国全
YANG Xia;YANG ZhongHan;ZHOU Ti;QI WeiWei;GAO GuoQuan(Department of Biochemistry,Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou 510080,China)
出处
《中国科学：生命科学》
CSCD
北大核心
2020年第10期1055-1067,共13页
Scientia Sinica(Vitae)
